{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:13:16Z","timestamp":1762866796348,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.revmed.2015.12.027","type":"journal-article","created":{"date-parts":[[2016,1,28]],"date-time":"2016-01-28T10:17:33Z","timestamp":1453976253000},"page":"701-704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacit\u00e9 de l\u2019\u00e9culizumab comme traitement de la microangiopathie thrombotique induite par la gemcitabine\u00a0: \u00e0 propos d\u2019un cas"],"prefix":"10.1016","volume":"37","author":[{"given":"T.","family":"Rogier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gerfaud-Valentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pouteil-Noble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Taleb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Guillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Noel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Broussolle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2015.12.027_bib0130","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.12.027_bib0135","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2015.12.027_bib0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","article-title":"Phase\u00a0II trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas","volume":"12","author":"Casper","year":"1994","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.revmed.2015.12.027_bib0145","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00280-008-0900-x","article-title":"Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report","volume":"64","author":"Bharthuar","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0155","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00280-010-1258-4","article-title":"Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome (TTP\/HUS) with rituximab","volume":"65","author":"Gourley","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0160","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.12.027_bib0165","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","article-title":"Cancer awareness in atypical thrombotic microangiopathies","volume":"14","author":"Oberic","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.revmed.2015.12.027_bib0170","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168\u00a0reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine"},{"key":"10.1016\/j.revmed.2015.12.027_bib0175","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","article-title":"A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy","volume":"85","author":"Fung","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2015.12.027_bib0180","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0272-6386(99)70194-0","article-title":"Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine","volume":"33","author":"Flombaum","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.revmed.2015.12.027_bib0185","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000435807","article-title":"Improvement in gemcitabine-induced thrombotic microangiopathy with rituximab in a patient with ovarian cancer: mechanistic considerations","volume":"5","author":"Murugapandian","year":"2015","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.revmed.2015.12.027_bib0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5527\/wjn.v2.i3.56","article-title":"Update on hemolytic uremic syndrome: diagnostic and therapeutic recommendations","volume":"2","author":"Salvadori","year":"2013","journal-title":"World J Nephrol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0195","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bjh.12686","article-title":"Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy","volume":"164","author":"Starck","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0200","first-page":"E30","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5009\/gnl.2014.8.1.109","article-title":"Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature","volume":"8","author":"Lee","year":"2014","journal-title":"Gut Liver"},{"key":"10.1016\/j.revmed.2015.12.027_bib0210","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Izzedine","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2015.12.027_bib0215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1346-8138.2011.01353.x","article-title":"Livedo reticularis as an initial clinical manifestation of gemcitabine-induced hemolytic uremic syndrome","volume":"39","author":"Zemtsov","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0220","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1600-0560.2012.01918.x","article-title":"Gemcitabine-associated livedoid thrombotic microangiopathy with associated sclerema neonatorum-like microscopic changes","volume":"39","author":"Mir-Bonaf\u00e9","year":"2012","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0225","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0230","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1159\/000013525","article-title":"Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy","volume":"19","author":"Lhotta","year":"1999","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.revmed.2015.12.027_bib0235","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/jca.20213","article-title":"Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?","volume":"24","author":"Gore","year":"2009","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.revmed.2015.12.027_bib0240","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ejim.2015.07.021","article-title":"Rituximab in autoimmune thrombotic thrombocytopenic purpura: a success story","volume":"26","author":"Froissart","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.revmed.2015.12.027_bib0245","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2015.12.027_bib0125","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.revmed.2014.10.364","article-title":"[The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy]","volume":"36","author":"Sauv\u00e8tre","year":"2015","journal-title":"Rev Med Interne"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631501142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631501142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:36:54Z","timestamp":1759336614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886631501142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S024886631501142X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2015.12.027","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacit\u00e9 de l\u2019\u00e9culizumab comme traitement de la microangiopathie thrombotique induite par la gemcitabine\u00a0: \u00e0 propos d\u2019un cas","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2015.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}